Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(21 sites)
Australia
Calvary Mater Newcastle, Waratah, New South Wales One Clinical Research Perth, Perth, Western Australia Georgia
Arensia Exploratory Medicine, LLC, Tbilisi Germany
SLK Kliniken Heilbronn GmbH, Heilbronn, Baden-Wurttemberg Netherlands
Radboud Universitair Medisch Centrum, Nijmegen, Gelderland Poland
Centrum Medyczne Poznan - PRATIA - PPDS, Poznan, Greater Poland Voivodeship MCM Krakow - PRATIA - PPDS, Krakow Romania
Prof. Dr. Alexandru Trestioreanu Oncologic Institute, Bucharest Prof Dr I Chiricuta Institute of Oncology, Cluj-Napoca Spain
Clinica Universidad Navarra, Pamplona, Navarre NEXT - Hospital Quironsalud Barcelona, Barcelona Hospital Universitari Vall D'Hebron, Barcelona Hospital Clinic de Barcelona, Barcelona Institut Catala d'Oncologia de Badalona, Barcelona Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas de Gran Canaria Instituto de Investigación Sanitaria Fundación Jimenez Díaz, Madrid Hospital Universitario 12 De Octubre, Madrid NEXT - Hospital Universitario Quironsalud Madrid, Madrid Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda Universitary Hospital Virgen Macarena, Seville Hospital Clinico Universitario de Valencia, Valencia